JNJ.DE Johnson & Johnson (XETRA) €186.76 intraday on 16 Jan 2026: watch earnings due 21 Jan
We see JNJ.DE stock trading at €186.76 intraday on 16 Jan 2026 ahead of Johnson & Johnson’s earnings report scheduled for 21 Jan 2026. The near-term catalyst is the company’s quarterly results and updated guidance. Investors should focus on margin trends, pharmaceutical launches, and MedTech sales versus consensus. This piece previews metrics, valuation, and a short-term model forecast to set expectations before the result.
Earnings timing and short-term catalyst for JNJ.DE stock
Johnson & Johnson reports next on 21 Jan 2026, a key catalyst for JNJ.DE stock. The earnings announcement follows a quiet intraday move from €183.06 low to €187.26 high today. Traders should watch revenue growth, core EPS versus the current EPS €8.90 and commentary on product cycles.
Pre-report volatility can widen; average volume is 3,620.00 versus today’s 5,553.00, indicating slightly higher activity ahead of the release. For background reading on market commentary use CNBC and MarketBeat previews source source.
Valuation and financials in focus for JNJ.DE stock
Johnson & Johnson trades at PE 21.08 on reported EPS €8.90, offering a lower multiple than the Healthcare sector average PE 31.80. Price-to-sales is 5.69, price-to-book is 6.67, and dividend yield is 2.37%. These exact ratios frame current valuation for JNJ.DE stock.
Key balance metrics: market cap €451.94B, price 50-day average €175.21, price 200-day average €152.37. Free cash flow per share is €7.85, and debt-to-equity is 0.08, indicating low leverage compared with peers.
Price action, liquidity and technicals for JNJ.DE stock
Intraday price is €186.76 with day range €183.06–€187.26 and year range €128.16–€188.06. Average volume is 3,620.00 and today’s volume is 5,553.00, so liquidity is normal for XETRA trading in Germany. Momentum indicators show RSI 51.93 and ATR 2.79, suggesting balanced momentum.
Technical setup for JNJ.DE stock: the 50-day average €175.21 sits below the current price, supporting the near-term trend, while MACD histogram at -0.72 signals caution ahead of the release.
Meyka AI grade and forecast for JNJ.DE stock
Meyka AI rates JNJ.DE with a score out of 100: 72.11 (B+) — BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and are for informational use only.
Meyka AI’s forecast model projects a monthly price €184.28 and a yearly price €151.18. Compared with the current €186.76, the monthly model implies -1.33% near-term downside and the yearly model implies -19.06%. Forecasts are model-based projections and not guarantees.
Analyst context and price target signals for JNJ.DE stock
External analyst signals are mixed but tilting positive: a recent firm rating lists Johnson & Johnson as A / Buy (15 Jan 2026) and MarketBeat shows a $213.33 US price target on NYSE coverage. Currency and market differences matter when viewing US targets from XETRA-listed JNJ.DE stock.
For XETRA investors we propose a near-term target range: conservative €170.00 and base-case €205.00 over 12 months, reflecting product cadence, dividend support (payout ratio 48.70%), and MedTech momentum. Adjust targets for your currency and tax profile.
Risks and opportunities for JNJ.DE stock
Opportunity: stable cash flow and pipeline therapies support durable returns; return on equity is 32.69%, and free cash flow yield is 3.63%, favoring shareholder returns and buybacks. Product launches or stronger-than-expected Pharma sales could drive upside for JNJ.DE stock.
Risk: pending litigation, slower Pharma launches, or weaker MedTech volumes would pressure margins and the PE multiple. Monitor organic revenue growth, R&D expense trends (17.05% of revenue), and guidance at the earnings call.
Final Thoughts
JNJ.DE stock is trading €186.76 intraday on 16 Jan 2026 with earnings due 21 Jan 2026, and the report should clarify near-term revenue and margin direction. Valuation sits at PE 21.08, below the Healthcare peer average, while the company shows healthy ROE 32.69% and low leverage debt-to-equity 0.08. Meyka AI’s model projects €184.28 for the month and €151.18 for the year, implying -1.33% near-term and -19.06% 12-month downside versus the current price; these are model-based projections and not guarantees. Our view: strength through diversified Consumer, Pharma and MedTech franchises supports a B+ (72.11) grade from Meyka AI, but investors should weigh that against guidance risk and currency differences for NYSE targets. Watch the upcoming earnings release for forward guidance, margins, and any MedTech order trends. For direct quotes and real-time updates see the JNJ.DE page on Meyka and external previews from CNBC and MarketBeat JNJ.DE stock page on Meyka source source.
FAQs
When does Johnson & Johnson report earnings and why does it matter for JNJ.DE stock?
Johnson & Johnson reports on 21 Jan 2026. That report matters for JNJ.DE stock because investors will get fresh revenue, EPS data, and guidance that can move the price and clarify MedTech and Pharma momentum.
What are the key valuation metrics to watch for JNJ.DE stock?
Key metrics are PE 21.08, EPS €8.90, price-to-sales 5.69, and dividend yield 2.37%. These ratios help compare JNJ.DE stock with Healthcare peers and assess relative value.
What does Meyka AI forecast for JNJ.DE stock and how should I use it?
Meyka AI’s forecast model projects €184.28 monthly and €151.18 yearly for JNJ.DE stock. Use these as scenario inputs, not guarantees, and combine them with earnings guidance and analyst updates before trading.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
